Aktieanalys

Alzinova: New Encouraging Interim Data From Phase Ib Study - Redeye

{newsItem.title}

Redeye Publicerad: 05 May 2023 08:56

Redeye comments on the new positive data from the second interim analysis of the ongoing phase Ib study with Alzinova’s vaccine candidate ALZ-101.

Länk till analysen i sin helhet: https://www.redeye.se/research/902932/alzinova-new-encouraging-interim-data-from-phase-ib-study?utm_source=finwire&utm_medium=RSS

Nyheter om Alzinova

Läses av andra just nu

Om aktien Alzinova

Senaste nytt